ArticleJMIR dermatology2026
Topical Recombinant Collagen Following Fractional Radio Frequency Microneedling for Nonsurgical Facelift: Case Report.
Article in JMIR dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fractional radio frequency microneedling (FRM) is an effective nonsurgical facelift modality supported by growing clinical evidence. While generally well tolerated, postprocedural erythema, pain, swelling, and bruising typically last up to 7 days. Other serious complications include prolonged swelling, infection, persistent grid mark, burns, and hypo- or hyperpigmentation. Recombinant human collagen has demonstrated potent wound-healing and anti-inflammatory properties, which could be harnessed for post-FRM recovery. Objective: To date, there is a lack of published studies evaluating the use of topical agents to improve postprocedural recovery following FRM. This case report describes the early experience of using topical recombinant collagen post FRM for nonsurgical facelift. Methods: Two 40-year-old female patients with Fitzpatrick skin type IV underwent FRM for nonsurgical facelift. The procedure was performed with standard energy settings. Immediately post procedure, topical recombinant collagen was applied to the treated areas. Either clinical photography or cross-polarized imaging was used to objectively capture the changes in facial erythema and swelling. Results: Both cases demonstrated a marked reduction of erythema and inflammation within 1 to 2 hours after application of topical recombinant collagen. These observations appeared earlier compared to the typical timeframe of 1 to 3 days. No adverse events were reported. Conclusions: Topical recombinant collagen application post FRM was associated with an early reduction of skin erythema and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.